Detalles de la búsqueda
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272527
2.
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Blood
; 143(2): 152-165, 2024 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37832030
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34891224
4.
Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Br J Haematol
; 199(2): 230-238, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961783
5.
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort.
Eur J Haematol
; 108(5): 437-445, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35122325
6.
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 195(3): 388-398, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34590303
7.
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Br J Haematol
; 188(4): 501-510, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31588567
8.
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Br J Haematol
; 189(4): 661-671, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017050
9.
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Br J Haematol
; 181(6): 782-790, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29741758
10.
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Haematologica
; 101(7): 872-8, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27081177
11.
Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Biol Blood Marrow Transplant
; 21(8): 1437-44, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25865648
12.
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Haematologica
; 100(10): 1327-33, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26250580
13.
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Haematologica
; 100(10): 1334-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160879
14.
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
Blood
; 120(22): 4292-5, 2012 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23047823
15.
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.
Br J Haematol
; 158(2): 174-185, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22640008
16.
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Blood
; 114(3): 522-5, 2009 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19332768
17.
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant
; 16(5): 639-46, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20005967
18.
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Haematologica
; 100(2): e63-7, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425684
19.
IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two cases.
Hematology
; 25(1): 335-340, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893754
20.
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Biol Blood Marrow Transplant
; 15(2): 205-13, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19167680